Soleno Therapeutics Faces Investigation Over VYKAT™ XR Misstatements as Stock Plummets 40%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy SLNO?
Source: PRnewswire
- Legal Investigation Initiated: Shareholder rights law firm Johnson Fistel is investigating whether Soleno violated federal securities laws by making false statements regarding VYKAT™ XR, which could undermine investor confidence and lead to significant legal repercussions.
- Product Launch Challenges: Despite receiving FDA approval for VYKAT™ XR in September 2025, Soleno acknowledged during its November earnings call that it faced challenges such as a slowdown in new treatment initiations and increased therapy discontinuations, indicating potential risks to market acceptance and revenue.
- Impact of Short Seller Report: In August 2025, short seller Scorpion Capital issued a report questioning the safety and commercialization plans for VYKAT™ XR, resulting in a nearly 40% decline in Soleno's stock price from August 14 to November 5, highlighting investor concerns about the sustainability of its business model.
- Investor Loss Risk: The significant stock volatility raises concerns for investors who purchased Soleno securities during this period, as they may face substantial losses and potential legal actions, further intensifying the company's financial and reputational challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.680
Low
75.00
Averages
110.50
High
125.00
Current: 39.680
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Soleno Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Soleno Therapeutics in the Northern District of California on behalf of investors who purchased shares between March 26, 2025, and November 4, 2025, alleging the company concealed significant safety concerns regarding its DCCR drug.
- Allegation Details: The complaint claims that Soleno systematically downplayed and failed to disclose serious safety issues related to DCCR, including fluid retention in clinical trial participants, which posed greater risks than communicated to investors.
- Business Impact: The lack of transparency regarding DCCR's commercial viability and associated risks has led to investor losses following the revelation of true information, potentially resulting in a significant stock price decline and damaging the company's reputation and future financing capabilities.
- Next Steps: Investors must apply by May 5, 2026, to be appointed as lead plaintiffs in the lawsuit, with the law firm offering free consultations to encourage affected investors to understand their legal rights and options.
See More
Class Action Reminder for Soleno Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds all shareholders who purchased Soleno Therapeutics (NASDAQ:SLNO) stock between March 26, 2025, and November 4, 2025, that a class action has been filed, alleging the company failed to disclose safety concerns regarding the DCCR clinical trial, potentially leading to significant investor losses.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during its Phase 3 clinical trial, including fluid retention in participants, which could materially lower the drug's commercial viability and affect patient willingness to use it.
- Stock Price Volatility: Following the release of a report by Scorpion Capital on August 15, 2025, detailing issues with Soleno's clinical trials, the stock price declined nearly 12% over two trading days; additionally, after a patient death linked to DCCR was reported on September 10, 2025, the stock fell nearly 19% in two days.
- Financial Impact: On November 4, 2025, Soleno reported its third-quarter financial results, with the CEO stating that the Scorpion report caused a
See More
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics (NASDAQ:SLNO) stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, reflecting the law firm's commitment to protecting investor rights and interests in the face of potential financial harm.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno failed to disclose significant safety concerns related to its DCCR drug during clinical trials, which could lead to higher risks for investors post-launch, thereby impacting the company's reputation and future market performance.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
See More
Faruqi & Faruqi Investigates Soleno Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Soleno Therapeutics (NASDAQ: SLNO), specifically urging investors who purchased securities between March 26, 2025, and November 4, 2025, to seek lead plaintiff status in a class action by the May 5, 2026 deadline.
- Safety Concerns Exposed: The complaint alleges that Soleno and its executives systematically downplayed and concealed significant safety concerns related to the DCCR Phase 3 clinical trial, including issues of fluid retention in participants, which raises serious questions about the drug's commercial viability and future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, which raised major concerns about the drug's safety and efficacy, Soleno's stock price plummeted nearly 12% from $77 to $68 over two days; additionally, after the Q3 financial results were released on November 4, 2025, the stock fell 27% from $64 to $47, reflecting market pessimism about the company's outlook.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding Soleno's conduct, including whistleblowers and former employees, to contact the firm directly to better protect investor rights and advance the case.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and its executives, seeking damages for investors who purchased securities between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential risks associated with the company.
- Safety Concerns Allegations: The complaint alleges that Soleno failed to disclose significant safety concerns related to its DCCR clinical trial, including issues of fluid retention in participants, indicating that the safety risks of the drug were severely underestimated, potentially leading to greater losses for investors.
- Declining Commercial Viability: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, which may result in higher patient discontinuation rates, reduced prescriber willingness, and potential regulatory actions, further impacting the company's market performance and investor confidence.
- Investor Action Recommendations: Affected investors must apply to be lead plaintiffs by May 5, 2026, to participate in any recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial burden on investors.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety risks associated with its DCCR drug during the period from March 26 to November 4, 2025, with investors having until May 5, 2026, to apply as lead plaintiffs, indicating significant legal risks for the company.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed serious safety issues during clinical trials, including fluid retention in participants, which has severely undermined investor confidence in the company's future prospects.
- Stock Price Volatility: Following a critical report from Scorpion Capital in August 2025, Soleno's stock price dropped nearly 12% over two trading days, and after a patient death was reported in September, the stock fell approximately 19%, reflecting a drastic decline in market trust in its products.
- Severe Legal Consequences: In November 2025, Soleno acknowledged in its financial report that the launch of DCCR was disrupted, with a decrease in patient start forms and increased discontinuation rates, leading to a further 27% drop in stock price over two days, highlighting the profound impact of legal and market pressures on the company's future growth.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Soleno Therapeutics in the Northern District of California on behalf of investors who purchased shares between March 26, 2025, and November 4, 2025, alleging the company concealed significant safety concerns regarding its DCCR drug.
- Allegation Details: The complaint claims that Soleno systematically downplayed and failed to disclose serious safety issues related to DCCR, including fluid retention in clinical trial participants, which posed greater risks than communicated to investors.
- Business Impact: The lack of transparency regarding DCCR's commercial viability and associated risks has led to investor losses following the revelation of true information, potentially resulting in a significant stock price decline and damaging the company's reputation and future financing capabilities.
- Next Steps: Investors must apply by May 5, 2026, to be appointed as lead plaintiffs in the lawsuit, with the law firm offering free consultations to encourage affected investors to understand their legal rights and options.
See More
Class Action Reminder for Soleno Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds all shareholders who purchased Soleno Therapeutics (NASDAQ:SLNO) stock between March 26, 2025, and November 4, 2025, that a class action has been filed, alleging the company failed to disclose safety concerns regarding the DCCR clinical trial, potentially leading to significant investor losses.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during its Phase 3 clinical trial, including fluid retention in participants, which could materially lower the drug's commercial viability and affect patient willingness to use it.
- Stock Price Volatility: Following the release of a report by Scorpion Capital on August 15, 2025, detailing issues with Soleno's clinical trials, the stock price declined nearly 12% over two trading days; additionally, after a patient death linked to DCCR was reported on September 10, 2025, the stock fell nearly 19% in two days.
- Financial Impact: On November 4, 2025, Soleno reported its third-quarter financial results, with the CEO stating that the Scorpion report caused a
See More
Class Action Lawsuit Announced for Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics (NASDAQ:SLNO) stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, reflecting the law firm's commitment to protecting investor rights and interests in the face of potential financial harm.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno failed to disclose significant safety concerns related to its DCCR drug during clinical trials, which could lead to higher risks for investors post-launch, thereby impacting the company's reputation and future market performance.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
See More
Faruqi & Faruqi Investigates Soleno Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Soleno Therapeutics (NASDAQ: SLNO), specifically urging investors who purchased securities between March 26, 2025, and November 4, 2025, to seek lead plaintiff status in a class action by the May 5, 2026 deadline.
- Safety Concerns Exposed: The complaint alleges that Soleno and its executives systematically downplayed and concealed significant safety concerns related to the DCCR Phase 3 clinical trial, including issues of fluid retention in participants, which raises serious questions about the drug's commercial viability and future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, which raised major concerns about the drug's safety and efficacy, Soleno's stock price plummeted nearly 12% from $77 to $68 over two days; additionally, after the Q3 financial results were released on November 4, 2025, the stock fell 27% from $64 to $47, reflecting market pessimism about the company's outlook.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding Soleno's conduct, including whistleblowers and former employees, to contact the firm directly to better protect investor rights and advance the case.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and its executives, seeking damages for investors who purchased securities between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential risks associated with the company.
- Safety Concerns Allegations: The complaint alleges that Soleno failed to disclose significant safety concerns related to its DCCR clinical trial, including issues of fluid retention in participants, indicating that the safety risks of the drug were severely underestimated, potentially leading to greater losses for investors.
- Declining Commercial Viability: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, which may result in higher patient discontinuation rates, reduced prescriber willingness, and potential regulatory actions, further impacting the company's market performance and investor confidence.
- Investor Action Recommendations: Affected investors must apply to be lead plaintiffs by May 5, 2026, to participate in any recovery, with the law firm promising to charge fees only upon success, thereby reducing the financial burden on investors.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety risks associated with its DCCR drug during the period from March 26 to November 4, 2025, with investors having until May 5, 2026, to apply as lead plaintiffs, indicating significant legal risks for the company.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed serious safety issues during clinical trials, including fluid retention in participants, which has severely undermined investor confidence in the company's future prospects.
- Stock Price Volatility: Following a critical report from Scorpion Capital in August 2025, Soleno's stock price dropped nearly 12% over two trading days, and after a patient death was reported in September, the stock fell approximately 19%, reflecting a drastic decline in market trust in its products.
- Severe Legal Consequences: In November 2025, Soleno acknowledged in its financial report that the launch of DCCR was disrupted, with a decrease in patient start forms and increased discontinuation rates, leading to a further 27% drop in stock price over two days, highlighting the profound impact of legal and market pressures on the company's future growth.
See More
